AMAlexander Mischnik

Alexander Mischnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Mischnik has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Axel Hamprecht

    Carl von Ossietzky University Oldenburg

    3 shared publications
  • Harald Seifert

    German Center for Infection Research (DZIF), Germany; Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne, Cologne, Germany

    3 shared publications
  • Nico Tom Mutters

    University Bonn, University hospital Bonn, Institute for Hygiene and Public Health, Bonn, Germany

    3 shared publications
  • Petra Gastmeier

    Campus Benjamin Franklin

    3 shared publications
  • Winfried V. Kern

    German Center for Infection Research (DZIF), Germany; Division of Infectious Diseases, Department of Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Germany

    3 shared publications
  • Anna Rohde

    German Center for Infection Research (DZIF), Germany; Institute for Hygiene and Environmental Medicine, National Reference Centre for the Surveillance of Nosocomial Infections, Charité-University Hospital Berlin, Berlin, Germany

    2 shared publications

Latest Publications

  • Pyogener Leberabszess: Erregerprofil und Konsequenzen für Diagnostik und Therapie

    by Alexander Mischnik, Winfried Vincenz Kern, Robert Thimme

    Liver abscess is a rare but potentially fatal disease with mortality rates of 2 – 12 %. The spectrum of causative microorganisms varies across the world and is changing due to increasing worldwide travel activity. As a result, previously less frequent pathogens must increasingly be considered in the differential diagnosis. The most common pathogens of liver abscess are so-called abscess streptococci, anaerobes and Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae. Certain clones among the Gram-negatives, typically among Klebsiella spp., harbour specific virulence factors and are therefore referred to as hypervirulent clones which spread worldwide. In any case, the causative agent should be identified before anti-infective treatment is initiated. Several pathogens such as Candida spp., Pseudomonas aeruginosa or Staphylococcus aureus are uncommon and only detected in a specific context. Various therapeutic regimens are available for anti-infective therapy. Usually an empirical therapy is started, combining mostly β-lactam antibiotics or quinolones with anaerobically active substances.


  • Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

    by Alexander Mischnik, Philipp Baumert, Axel Hamprecht, Anna Rohde, Silke Peter, Susanne Feihl, Johannes Knobloch, Hanna Gölz, Axel Kola, Birgit Obermann, et al.


  • Open Access

    In vitrosusceptibility to 19 agents other than β-lactams among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

    by A. Mischnik, P. Baumert, A. Hamprecht, A. M. Rohde, S. Peter, S. Feihl, J. Knobloch, H. Gölz, A. Kola, B. Obermann, et al.

    Objectives: As part of the multicentre Antibiotic Therapy Optimisation Study, MIC values of 19 non-β-lactam agents were determined for third-generation cephalosporin-resistant Escherichia coli, Klebsiella species and Enterobacter species (3GCREB) isolates collected in German hospitals. Methods: A total of 328 E. coli, 35 Klebsiella spp. (1 Klebsiella oxytoca and 34 Klebsiella pneumoniae) and 16 Enterobacter spp. (1 Enterobacter aerogenes and 15 Enterobacter cloacae) isolates were submitted to broth microdilution antimicrobial susceptibility testing with the MICRONAUT system. MICs of fluoroquinolones (levofloxacin and moxifloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin and paromomycin), tetracyclines (tetracycline, minocycline and tigecycline), macrolides (erythromycin, clarithromycin and azithromycin) and miscellaneous agents [trimethoprim/sulfamethoxazole, chloramphenicol, nitrofurantoin, colistin and fosfomycin intravenous (iv)] were determined and reviewed against 2016 EUCAST breakpoints. Results: The MIC of levofloxacin was >2 mg/L for 128 of 328 E. coli and 8 of 35 Klebsiella spp., but only 1 of 16 Enterobacter spp. Rates of resistance to trimethoprim/sulfamethoxazole were high (>70%), except for Enterobacter spp. Rates of resistance to colistin and fosfomycin iv were still low. About 20% of the tested isolates were resistant to chloramphenicol. Only 1 (of 328) E. coli isolate had an MIC of amikacin >16 mg/L and only 33 of 328 E. coli and 1 of 35 Klebsiella spp. had an MIC of tobramycin >4 mg/L, whereas average gentamicin MICs were in general more elevated. A tigecycline MIC >2 mg/L was only found for 1 of 16 Enterobacter spp., but in none of the E. coli or Klebsiella spp. isolates. Conclusions: Our study gives insight into previously unreported non-β-lactam MIC distributions of 3GCREB isolates.


  • Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

    by Alexander Mischnik, Philipp Baumert, Axel Hamprecht, Anna Rohde, Silke Peter, Susanne Feihl, Johannes Knobloch, Hanna Gölz, Axel Kola, Birgit Obermann, et al.


  • Klinische Bedeutung von Infektionen durch Carbapenem-resistente Enterobakterien bei Lebertransplantierten

    by C. Lübbert, H. M. Hau, A. Rodloff, J. Mössner, A. Mischnik, S. Bercker, M. Bartels, U. X. Kaisers

    Infektionen durch Carbapenem-resistente Enterobakterien (CRE) stellen aufgrund ihrer hohen Morbidität und Mortalität weltweit eine wachsende Bedrohung für Lebertransplantatempfänger (LTR) dar, v. a. bei Nachweis von Klebsiella pneumoniae Carbapenemase (KPC)-bildenden Erregern. Nach der aktuellen Literatur entwickeln 3 bis 13 % der Organtransplantierten in Endemiegebieten Infektionen durch CRE, wobei der primäre Infektionsort eng mit dem transplantierten Organ im Zusammenhang steht. Die kumulative 30-Tage-Sterblichkeit von LTR mit Infektionen durch Carbapenem-resistente K. pneumoniae liegt bei 36 %, und die 180-Tage-Mortalitätsrate beträgt 58 %. Die hohe Anfälligkeit von LTR für potenziell tödlich verlaufende bakterielle Infektionen mit multiresistenten Erregern (MRE) führt in der Praxis zu einer häufigeren empirischen Anwendung von erweiterten Breitspektrum-Antibiotikatherapien, die wiederum die Selektion extremer Resistenzen fördert. Dennoch besteht eine relevante Gefahr des Scheiterns der herkömmlichen empirischen Behandlung, da kulturbasierte Techniken zur mikrobiologischen Identifikation von CRE eine 48- bis 72-stündige Verzögerung von der Abnahme der Blutkulturen bis zur mikrobiologischen Befunderstellung mit Resistenztestung beinhalten, sodass zielgerichtete Therapien nur verzögert begonnen werden können. Dieser Teufelskreis ist schwer zu durchbrechen und führt zu einer fortwährenden Einengung der antibiotischen Behandlungsmöglichkeiten. Da die derzeit verfügbaren therapeutischen Optionen äußerst begrenzt sind, kommt der Infektionsprävention eine herausragende Bedeutung zu, v. a. in der Frühphase nach Lebertransplantation mit intensiver Immunsuppression. Die Verbesserung klinischer Behandlungsergebnisse ist eine große Herausforderung und erfordert einen mehrgliedrigen Ansatz, bei dem stringent praktizierte Hygienemaßnahmen, Screening-Tests auf MRE, zeitsparende molekularbiologische Untersuchungstechniken und Antibiotic Stewardship (ABS) kombiniert werden. Dieser Artikel stellt die aktuelle Literatur in Bezug auf die Häufigkeit und das klinische Outcome von CRE-Infektionen bei LTR vor und fasst aktuelle präventive und therapeutische Empfehlungen zusammen, um die Bedrohung durch CRE im Real-Life-Setting der klinischen Transplantationsmedizin zu minimieren. Infections with carbapenem-resistant Enterobacteriaceae (CRE) are an emerging cause of morbidity and mortality among liver transplant recipients (LTR) worldwide, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing organisms. Approximately 3 – 13 % of solid organ transplant recipients in CRE-endemic areas develop CRE infections, and the infection site correlates with the transplanted organ. The cumulative 30-day mortality rate of LTR infected with carbapenem-resistant K. pneumoniae is 36 %, and the 180-day mortality rate is 58 %. Awareness of the high vulnerability of LTR to fatal bacterial infection leads to the more frequent use of ultrabroad-spectrum empirical antibiotic therapy, which further contributes to the selection of extreme drug resistance. Moreover, it comprises a relevant risk of failure to initiate adequate empirical treatment due to the fact that culture-based techniques used to identify CRE imply a 48- to 72-hour delay from blood culture collection until administration of the targeted therapy. This vicious circle is difficult to avoid and leads to increased clinical intricacy and narrowed antimicrobial therapeutic options. Because available options are extremely limited, infection prevention measures have gained outstanding importance, particularly in the phase after liver transplant requiring intense immunosuppression early on. Improving clinical outcomes is a major challenge and involves a multi-targeted approach combining strictly applied hygiene measures, active surveillance tests, the use of modern, time-saving methods of molecular biology, and enforced antibiotic stewardship. This article reviews the current literature regarding the incidence and outcome of CRE infections in LTR, and it summarises current preventive and therapeutic recommendations to minimise the threat by CRE in real-life clinical transplant settings. * beide Autoren haben einen gleichwertigen Beitrag zur Publikation geleistet.


  • Open Access

    Influx of multidrug-resistant organisms by country-to-country transfer of patients

    by Nico T. Mutters, Frank Günther, Anja Sander, Alexander Mischnik, Uwe Frank

    Multidrug-resistant organisms (MDRO) are a worldwide problem. International migration and travel facilitate the spread of MDRO. Therefore the goal of our study was to assess the risk of influx of MDRO from patients transferred to one of Central Europe’s largest hospitals from abroad. A mono-centre study was conducted. All patients transferred from other countries were screened; additional data was collected on comorbidities, etc. Presence of carbapenemases of multidrug-resistant Gram-negatives was confirmed by PCR. The association between length of stay, being colonized and/or infected by a MDRO, country of origin, diagnosis and other factors was assessed by binomial regression analyses. From 2012 to 2013, one fifth of all patients were colonized with MDRO (Methicillin-resistant Staphylococcus aureus [4.1 %], Vancomycin-resistant Enterococci [2.9 %], multidrug-resistant Gram-negatives [12.8 %] and extensively drug-resistant Gram-negatives [3.4 %]). The Gram-negatives carried a variety of carbapenemases including OXA, VIM, KPC and NDM. The length of stay was significantly prolonged by 77.2 % in patients colonized with a MDRO, compared to those not colonized (p<0.0001). Country-to-Country transfer of patients to European hospitals represents a high risk of introduction of MDRO and infection control specialists should endorse containment and screening measures.


  • Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production

    by N. T. Mutters, S. Zimmermann, M. Kaase, A. Mischnik

    Treatment options for multidrug-resistant Gram-negative infections are scarce and therefore alternatives with a narrow spectrum or new agents are sought. Antimicrobial susceptibility to temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam was determined using Etest and disk diffusion according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology. A total of 77 carbapenem-nonsusceptible Enterobacteriaceae were studied, including Klebsiella pneumoniae (26 %), Escherichia coli (26 %), Enterobacter cloacae (26 %), and Enterobacter aerogenes (22 %). Several phenotypic tests, PCRs followed by sequencing and a microbiological bioassay excluded carbapenemase production in all isolates. Antimicrobial susceptibility rates were low for temocillin (15.6 %, minimum inhibitory concentration [MIC] range 2 to >1,024 μg/ml), moderate for mecillinam (59.7 %, MIC range 0.25 to >256 μg/ml), and excellent for ceftazidime/avibactam (100 %, zone diameter range 19 to 32 mm, median 25 mm). 5.2 % of the isolates were susceptible to ceftazidime alone (zone diameter range 6 to 32 mm). In this study, mecillinam exhibited moderate and ceftazidime/avibactam excellent in vitro antimicrobial activity against carbapenem-nonsusceptible Enterobacteriaceae without carbapenemase production. Ceftazidime/avibactam was able to restore previously reduced susceptibility to ceftazidime in all isolates, thus potentiating its activity. Temocillin only exhibited low in vitro antimicrobial activity against the isolates. Further evaluation of mecillinam and ceftazidime/avibactam with regard to the potential clinical utility against infections caused by these pathogens has to be performed.


  • Vancomycin-resistente Enterokokken: Erhöhte Sterblichkeit durch Tigecyclin?

    by Nico T. Mutters, Alexander Mischnik

    Die prinzipielle Bewertung des Potenzials von Tigecyclin geht über den Kern unseres Artikels hinaus, da in den Einsatzgebieten Pneumonie der Nachweis von Enterokokken keine Behandlungsindikation darstellt. Es trifft zu, dass es sich in der 2010 von der amerikanischen Food and Drug Association (FDA) herausgegebenen Warnung um die Gesamtletalität und nicht um die attributive Letalität handelt und daher unter Berücksichtigung des Zulassungsstatus von Tigecyclin der Unterschied in der Gesamtmortalität auf nur < 0,6 % sinkt [3].

  • Carbapenem-Resistenz bei Enterobakterien, Pseudomonas aeruginosa und Acinetobacter baumannii

    by Alexander Mischnik, Martin Kaase, Christoph Lübbert, Harald Seifert, Winfried V. Kern

    Epidemiologie: Neue Daten liefern Hinweise für einen Anstieg der Resistenzraten gegenüber Carbapenemen bei Enterobakterien und nicht-fermentierenden Gram-negativen Stäbchenbakterien („Nonfermentern“) wie Pseudomonas aeruginosa und Acinetobacter baumannii. Eine Charakterisierung der Carbapenemase ist epidemiologisch und therapeutisch hilfreich. Anforderungen an die mikrobiologische Diagnostik: Die In-vitro-Empfindlichkeit für Carbapeneme wird anhand der gemessenen minimalen Hemmkonzentration oder von Hemmhofdurchmessern bewertet und geschieht unabhängig von möglicherweise mit anderen Methoden nachgewiesenen Resistenzmechanismen („Report as measured“). Therapieoptionen: Kombinationstherapien sind in vielen Fällen einer Monotherapie überlegen. Der Einsatz von Carbapenemen bei nur mäßig erhöhter minimaler Hemmkonzentration kann trotz nachgewiesener Carbapenemase sinnvoll sein. In der Therapie werden daneben Tigecyclin, Colistin, Fosfomycin, Aminoglykoside und Aztreonam kombiniert. Eine Erhöhung der Dosis gegenüber den Empfehlungen der Fachinformation gilt für Colistin als gesichert, wird bei Meropenem empfohlen und kann auch bei Tigecyclin und Fosfomycin erwogen werden. Durch die verlängerte Infusionsdauer von Meropenem mit entsprechend längerer Dauer einer Konzentration oberhalb der minimalen Hemmkonzentration des Infektionserregers kann das Behandlungsergebnis verbessert werden.